Search results
Showing 2951 to 3000 of 4138 results for patient
Surgical insertion of a catheter-based intravascular microaxial flow pump for cardiogenic shock
In development Reference number: GID-IPG10461 Expected publication date: 25 March 2026
Awaiting development Reference number: GID-TA11748 Expected publication date: TBC
Awaiting development Reference number: GID-TA11769 Expected publication date: TBC
Low back pain and sciatica in over 16s: assessment and management (NG59)
This guideline covers assessing and managing low back pain and sciatica in people aged 16 and over. It outlines physical, psychological, pharmacological and surgical treatments to help people manage their low back pain and sciatica in their daily life. The guideline aims to improve people’s quality of life by promoting the most effective forms of care for low back pain and sciatica.
Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079]
In development Reference number: GID-TA10966 Expected publication date: TBC
Awaiting development Reference number: GID-TA11673 Expected publication date: TBC
In development Reference number: GID-TA11085 Expected publication date: TBC
In development Reference number: GID-TA11718 Expected publication date: TBC
Awaiting development Reference number: GID-TA11670 Expected publication date: TBC
Benralizumab for treating hypereosinophilic syndrome in people 12 years and over [ID6322]
Awaiting development Reference number: GID-TA11360 Expected publication date: TBC
Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over [ID6252]
Awaiting development Reference number: GID-TA11284 Expected publication date: TBC
Awaiting development Reference number: GID-TA11338 Expected publication date: TBC
In development Reference number: GID-TA10960 Expected publication date: TBC
In development Reference number: GID-TA11842 Expected publication date: TBC
Awaiting development Reference number: GID-TA11863 Expected publication date: TBC
In development Reference number: GID-TA11862 Expected publication date: TBC
Awaiting development Reference number: GID-TA11828 Expected publication date: TBC
Lipid disorders: FH assessment and diagnosis (historical readings) (IND260)
This indicator covers the percentage of patients with a total cholesterol reading greater than 7.5 mmol/litre when aged 29 years or under, or greater than 9.0 mmol/litre when aged 30 years or over, who have been: diagnosed with secondary hyperlipidaemia, or clinically assessed for familial hypercholesterolaemia, or referred for assessment for familial hypercholesterolaemia, or genetically diagnosed with familial hypercholesterolaemia. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM244
NICE has developed a medtech innovation briefing (MIB) on artificial intelligence in mammography .
Seven digital platforms supporting at home cardiac rehab given conditional recommendations
People with heart disease will be able to do their recovery sessions from home rather than travelling for rehabilitation appointments after our independent committee conditionally recommended 7 digital platforms for use in the NHS.
In development Reference number: GID-TA10998 Expected publication date: TBC
Daratumumab for treating high-risk smouldering multiple myeloma [ID6214]
Awaiting development Reference number: GID-TA11198 Expected publication date: TBC
In development Reference number: GID-TA11695 Expected publication date: TBC
In development Reference number: GID-TA11583 Expected publication date: TBC
In development Reference number: GID-TA11716 Expected publication date: TBC
In development Reference number: GID-TA11308 Expected publication date: TBC
In development Reference number: GID-TA11658 Expected publication date: TBC
Navepegritide for treating achondroplasia in people 2 to 15 years [ID6538]
In development Reference number: GID-TA11699 Expected publication date: TBC
In development Reference number: GID-TA11660 Expected publication date: TBC
Awaiting development Reference number: GID-IPG10418 Expected publication date: TBC
Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer [ID6433]
Awaiting development Reference number: GID-TA11489 Expected publication date: TBC
Adalimumab for treating early Dupuytren's contracture [ID6276]
Awaiting development Reference number: GID-TA11363 Expected publication date: TBC
In development Reference number: GID-TA11836 Expected publication date: TBC
Awaiting development Reference number: GID-TA11626 Expected publication date: TBC
In development Reference number: GID-TA11615 Expected publication date: TBC
In development Reference number: GID-TA11817 Expected publication date: TBC
In development Reference number: GID-IPG10318 Expected publication date: 25 March 2026
Percutaneous insertion of a catheter-based intravascular microaxial flow pump for cardiogenic shock
In development Reference number: GID-IPG10404 Expected publication date: 25 March 2026
In development Reference number: GID-TA11801 Expected publication date: TBC
In development Reference number: GID-TA11866 Expected publication date: TBC
Is the use of chlorhexidine body wash associated with increased antimicrobial resistance?
surgical and infection control teams, and should also take into account patient risk factors, such as whether the person is an S. aureus...
Bipolar, schizophrenia and other psychoses: cervical screening (IND85)
This indicator covers the percentage of women aged 25 or over and who have not attained the age of 65 with schizophrenia, bipolar affective disorder and other psychoses whose notes record that a cervical screening test has been performed in the preceding 5 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM20
This indicator covers the contractor establishing and maintaining a register of patients with atrial fibrillation, including patients with ‘AF resolved’. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM164
Novii Wireless Patch System for maternal and fetal monitoring (MIB228)
NICE has developed a medtech innovation briefing (MIB) on Novii Wireless Patch System for maternal and fetal monitoring .
In development Reference number: GID-TA11657 Expected publication date: 07 April 2027
Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059]
In development Reference number: GID-TA11036 Expected publication date: TBC
Awaiting development Reference number: GID-TA11639 Expected publication date: TBC
Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy ID6575
In development Reference number: GID-TA11742 Expected publication date: TBC